• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corporation - Common Stock (NQ:INCY)

    119.01 -1.03 (-0.86%)
    Delayed Quote Updated: 11:27 AM EST, Nov 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Incyte Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
    From Incyte
    Via Business Wire
    News headline image
    Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
    From Incyte
    Via Business Wire
    News headline image
    Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
    From Genmab A/S
    Via Business Wire
    News headline image
    Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Report Third Quarter Financial Results
    From Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    News headline image
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte Corporation
    Via Business Wire
    News headline image
    Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
    From Incyte
    Via Business Wire
    News headline image
    Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
    From Incyte
    Via Business Wire
    News headline image
    Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
    From Incyte
    Via Business Wire
    News headline image
    Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Report Second Quarter Financial Results
    From Incyte
    Via Business Wire
    News headline image
    Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
    From Incyte
    Via Business Wire
    News headline image
    Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    From Incyte Biosciences Japan G.K.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
    From Incyte
    Via Business Wire
    News headline image
    Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
    From Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From Incyte
    Via Business Wire
    News headline image
    Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
    From Genesis Molecular AI and Incyte
    Via Business Wire
    News headline image
    Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
    From Incyte and Edison Scientific
    Via Business Wire
    News headline image
    Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
    From Incyte
    Via Business Wire
    News headline image
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte Corporation
    Via Business Wire
    News headline image
    Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.